F. Brasó-Maristany

Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study

A. Rodriguez-Hernandez, O. Martínez-Sáez, F. Brasó-Maristany, B. Conte et autres

BACKGROUND: Germline (likely) pathogenic variants (PVs) are identified in 5%-10% of patients with breast cancer (BC) and play a critical role in guiding clinical management, including the use of targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). High-risk genes such …

es, us, it (code pays fourni par la source)

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers

Filipa Lynce, O. Martínez-Sáez, Benjamín Walbaum, F. Brasó-Maristany et autres

BACKGROUND: The HER2DX assay predicts long-term prognosis and pathologic complete response (pCR) in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving neoadjuvant systemic therapy but has not been evaluated in inflammatory breast cancer (IBC). PATIENTS AND METHODS: …

us, cl, es (code pays fourni par la source)

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

M. Martín, S.R. Stecklein, Oleg Gluz, Guillermo Villacampa et autres

BACKGROUND: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of …

es, us, de, ch, in, pe (code pays fourni par la source)

237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy

M. Martín Jiménez, Oleg Gluz, Guillermo Villacampa, Ulrike Nitz et autres

es, de, us (code pays fourni par la source)

136P Impact of ovarian stimulation on breast tumor biology: First results from a pilot study

Yasmina Barral El Gaoui, Dolors Manau, N. Chic, María Méndez et autres

The number of cycles of oocyte vitrification for fertility preservation is increasing annually. For young women with breast cancer facing fertility preservation, the impact of ovarian stimulation on tumor biology is unclear. Our pilot study explores this by analyzing breast tumor samples …

es (code pays fourni par la source)

8P Evaluating HER2DX pCR-Score and MRI response in predicting pathologic complete response (pCR) to anti-HER2 neoadjuvant chemotherapy (CT) in early-stage HER2-positive (HER2+) breast cancer (BC)

T. Pascual, O. Martínez-Sáez, L. Pare Brunet, G. Villacampa Javierre et autres

The predictive accuracy of the HER2DX pCR score for pCR following anti-HER2-based neoadjuvant CT, as compared to MRI response, is unknown. With the increasing reliance on MRI response in clinical trials for guiding surgical and systemic therapy decisions, understanding the discrimination ability …

es (code pays fourni par la source)

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

J. Cortés, Enrico Tagliafico, V. Guarneri, G. Griguolo et autres

Background: In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial topic. As an aid to treatment decisions, we aimed to develop a prognostic assay that integrates multiple data types for predicting survival outcome in patients with newly …

us (code pays fourni par la source)

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

A. Forero, María Ignacia Wehbi Vidal, P. Galván, A Llombart-Cussac et autres

Background: Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy. Methods: A …

us (code pays fourni par la source)